Next Article in Journal
Performance Assessment of SARS-CoV-2 PCR Assays Developed by WHO Referral Laboratories
Next Article in Special Issue
Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting—Role of Academic and Hybrid Modeling
Previous Article in Journal
Impact of Acute Hemoglobin Falls in Heart Failure Patients: A Population Study
Previous Article in Special Issue
Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices and Collaborating Care Sites
Open AccessReview

Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies

Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work and should be considered co-first authors.
J. Clin. Med. 2020, 9(6), 1870; https://doi.org/10.3390/jcm9061870
Received: 26 May 2020 / Revised: 12 June 2020 / Accepted: 12 June 2020 / Published: 15 June 2020
Non-small cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced with the identification of various key oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalizing therapy based on the molecular genomics of the tumor. This review presents approved treatments against actionable mutations in NSCLC as well as promising targets and therapies. We also discuss the current status of molecular testing practices in community oncology sites that would help to direct oncologists in lung cancer decision-making. We propose a collaborative framework between community practice and academic sites that can help improve the utilization of personalized strategies in the community, through incorporation of increased testing rates, virtual molecular tumor boards, vendor-based oncology clinical pathways, and an academic-type singular electronic health record system. View Full-Text
Keywords: non-small cell lung cancer; driver mutations; testing rates; receptor tyrosine kinases; team medicine non-small cell lung cancer; driver mutations; testing rates; receptor tyrosine kinases; team medicine
Show Figures

Figure 1

MDPI and ACS Style

Rajurkar, S.; Mambetsariev, I.; Pharaon, R.; Leach, B.; Tan, T.; Kulkarni, P.; Salgia, R. Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. J. Clin. Med. 2020, 9, 1870. https://doi.org/10.3390/jcm9061870

AMA Style

Rajurkar S, Mambetsariev I, Pharaon R, Leach B, Tan T, Kulkarni P, Salgia R. Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. Journal of Clinical Medicine. 2020; 9(6):1870. https://doi.org/10.3390/jcm9061870

Chicago/Turabian Style

Rajurkar, Swapnil; Mambetsariev, Isa; Pharaon, Rebecca; Leach, Benjamin; Tan, TingTing; Kulkarni, Prakash; Salgia, Ravi. 2020. "Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies" J. Clin. Med. 9, no. 6: 1870. https://doi.org/10.3390/jcm9061870

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop